Usefulness of endoscopic ultrasonography (EUS) for selecting carcinoid tumors as candidates to endoscopic resection.

INTRODUCTION: Carcinoid tumors (CTs) represent the most common type of neuroendocrine tumors (NETs). Digestive CTs in the gastroduodenal and colorectal tracts may be assessed using endoscopy and echoendoscopy or endoscopic ultrasonography (EUS) with the goal of attempting local resection with curative intent without having recourse to surgery. OBJECTIVE: Endpoints in this study included:--Assessing the usefulness of EUS for selecting CTs as candidates to endoscopic excision. --Assessing the effectiveness of local resection (complete carcinoid resection) and the safety (complications) of the technique involved. PATIENTS AND METHODS: OUr series included 18 patients (12 males and 6 females) with 23 tumors. Sixteen patients (10 males and 6 females) were selected, with age ranging from 40 to 81 years (mean: 57 years), biopsied, endoscopically treated digestive carcinoid tumors, and a previous negative extension study. Twenty-one 2-to-20-mm (mean size 8 mm) tumors were resected in 23 procedures. After endoscopy plus biopsy and echoendoscopy (EUS), excision was carried out with conventional polypectomy snare mucosectomy and submucosal injection with saline and/or adrenaline in most cases (15), and mucosectomy technique following lesion ligation with elastic bands for six cases. Two cases underwent transanal endoscopic surgery (TEM), one of them following non-curative polypectomy. A total of 23 local procedures were performed with the key goal of assessing efficacy (complete resection: CR) and safety (complications). RESULTS: There were no severe complications except for the last gastric mucosectomy for a 6-mm carcinoid, where a miniperforation occurred that was solved by using 3 clips (1/23: 4.3%).EUS sensitivity was 94%. Complete resection was 90.5% (19/21). CONCLUSIONS: The endoscopic mucosal resection of selected carcinoid tumors is a safe, effective technique. EUS is the technique of choice to select patients eligible for endoscopic resection (carcinoids smaller than 20 mm in superficial layers, with an unscathed muscularis propria and negative extension study).

[Interventionist endoscopic ultrasonography. A retrospective analysis of 60 procedures]. / Ultrasonografía endoscópica intervencionista. Análisis retrospectivo de 60 procedimientos.

INTRODUCTION AND OBJECTIVE: interventionist endoscopic ultrasonography is increasingly used because of its growing indications. We present here our retrospective and initial experience (60 procedures) with endoscopic ultrasonography (EUS) both for diagnosis (EUS-FNA) and therapy (EUS-guided tumorectomy and mucosectomy). PATIENTS AND METHOD: in a group with 27 cases including 10 submucosal tumors (SMTs), 2 adenopathies, and 15 potential pancreatic tumors (8 pancreatic cancers), a sectorial EUS-FNA at 7.5 MHz was performed for diagnosis prior to therapy (mainly surgical). A pancreatic pseudocyst was drained. In 21 cases with 27 SMTs (10 patients with 13 carcinoids) a tumorectomy was carried out using the standard loop or assisted polypectomy technique with submucosal injection, and in a few cases (two) using elastic band ligation following a radial EUS at 7.5, 12, or 20 MHz. In 6 cases of superficial gastroesophageal cancer or gastric dysplasia an endoscopic mucosal resection (classic EMR) was performed after EUS or MPs at 7.5 and 20 MHz. Fifty-five patients with 60 lesions, 29 femaes and 26 males with a mean age of 60 years (30-88 years) were retrospectively analyzed. RESULTS: diagnostic precision (P), sensitivity (S), specificity (Sp), positive predictive value (PPV), and negative predictive value (NPV) for EUS-FNA was 85, 83, 100, 100, and 43%, respectively, when comparing results with specimen histology. P was higher for adenopathies (100%) and pancreatic tumors (87%) than for SMTs (80%). No complications arose, except for one episode of upper gastrointestinal bleeding (UGIB) (3.7%) that was endoscopically and satisfactorily treated in a gastric SMT. In the group with 21 patients (10 carcinoids with 13 tumors) 27 SMTs were endoscopically treated by tumorectomy with no perforation and only 2 UGIBs (7.4%), one of them self-limited, recorded. Endoscopic resection was complete in 92% of cases. No complications occurred with classic EMR, and all patients are still alive with no evidence of relapse, either local or metastatic. In this group the rate of complete resections was 100%. CONCLUSIONS: EUS-FNA is a safe technique with high diagnostic accuracy. EUS-guided tumorectomy and mucosectomy are also safe and effective techniques in the endoscopic management of these tumors.

Endoscopic staging of low-grade gastric MALT lymphoma.

INTRODUCTION: Endoscopic ultrasonography (EUS) has already proven useful in the assessment of submucosal lesions, and the staging of gastrointestinal cancer, particularly gastric MALT-type lymphoma. The goal of this paper was EUS staging. PATIENTS AND METHOD: 24 patients (10 females, 14 males) with a median age of 56 years and possibly gastric MALT lymphoma (25 cases) were studied using videoendoscopy, biopsies, and echoendoscopy with 7.5- and 20-MHz radial EUS, and also with 12- and 20-MHz miniprobes (MPs). Nineteen patients were definitely evaluated (7 females, 12 males) as having 20 MALT-type lymphomas, as five patients were post-hoc disregarded when an invasive, high-grade gastric lymphoma (3c) or plasmocytoma (2c) was subsequently demonstrated. Of these 19 patients, all had T1 lesions except for two with T2 lesions; one patient had a gastroduodenal T1 lymphoma. Echographic findings with MPs were compared to EUS (gold standard) and histology both before and after eradication. Then, patients were followed up every 1-3-6 months using videoendoscopy and MPs. RESULTS: Echoendoscopy correctly identified T stages in 90% of cases. MPs identified T stages in 88% of cases, and N stages in 33% of cases, with results being slightly inferior to those obtained with conventional EUS (91 vs. 45%); they were consequently used for follow-up. After eradication, all but two patients are in complete remission and have been followed every 1-3-6 months using MPs without echographic abnormalities, except for a patient who relapsed.

Our cumulative experience with transendoscopic miniprobes.

INTRODUCTION: Transendoscopic miniprobes (TEMPs) have nowadays precise indications, but may become a diagnostic alternative to both radial and sectorial endoscopic ultrasonography (EUS) in the near future. PATIENTS AND METHODS: From November 1996 to July 2004 we carried out 620 examinations using TEMPs (124 during the last 12 months in 2003, with currently a mean of 11 examinations/month). Twenty explorations were performed with radial, 12.5 MHz (20 mm penetration), 6.2 F (2 mm diameter), 950 mm or 2000 mm Microvasive Endosound probes. Twenty explorations were performed using a 12 MHz (29 mm mean penetration) or 20 MHz (18 mm penetration) Olympus UM-2R/3R, or with a 12 MHz UM-DP12-25R or 20 MHz UM-DP20-25 R DPR-fitted Olympus probe, 2.5 mm in diameter and 2050 mm in length. A 20 MHz, 2.2 mm, wire-guided G20-29R was used for intraductal studies. In all, 580 examinations were carried out with both radial and linear, 12 MHz (240 E) or 20 MHz (60 E) Fuji probes, 2.6 mm in diameter and 1900 mm in length; and with a 7.5 MHz, 2.6 mm radial balloon microprobe with the well-known "preload" system that we have been using during the 1999-2004 period (280 E). Here we used a 3.2 mm working channel, whereas a 2.8 mm working channel was used with the remaining TEMPs. RESULTS: Twenty GI-tract examinations were performed with one Microvasive probe, which broke down when attempting its passage through the papilla. Currently we use a 20 MHz, 2.2 mm Olympus G20-29R guided microprobe for intraductal studies. We performed 100 gut examinations using one single Fuji TEMP (12 or 7.5 MHz). Organs explored included: esophagus and stomach, 60%; rectum and colon, 30%; other (duodenum, papilla, bile ducts), 10%. INDICATIONS: cancer staging, 35%; submucosal lesions, 30%; other, 35% (including 20% of esophageal non-tumoral conditions). COMPLICATIONS: aspiration, perforation, and mortality, 0%. Morbidity, 10%, at the expense of abdominal pain as induced by endoscopy itself. All strictures were successfully passed, except for one malignant stenosis in the rectum. CONCLUSIONS: During a 93-month period (1996-2004) we performed 620 explorations with TEMPs, with a current average of 11 examinations/month. TEMP durability is around 100 gut explorations. The esophagus and stomach were examined in 60% of cases. Primary indications included gut cancer staging and submucosal lesions (65%). Perforation and mortality rates amounted to 0%.

[Echo-endoscopy: the clinical implications after a period of more than 16 years of its existence]. / Ecoendoscopia: implicaciones clínicas después de un período de más de 16 años de existencia.

Endosonography is an imaging diagnostic technique recently introduced in our country. It allows us to perform an ultrasound from within the digestive tube. Because of the transducer proximity to the gut wall and the high frequency of emission we are able to visualize with great resolution small lesions as well as differentiate the five layers of the gastric wall and examine structures close to the digestive lumen with a 7 to 8 cm penetration. This is a brief introduction to the basic pillars of endosonography and its main indications, well defined after sixteen years of clinical practice.

Duodenogastric bile reflux and gastrointestinal motility in pathogenesis of functional dyspepsia. Role of cholecystectomy.

To establish the pathogenic role of duodenogastric reflux in dyspeptic symptoms we have compared the clinical features, gastrointestinal motility, and rates of duodenogastric bile reflux in 12 cholecistectomized dyspeptic patients, 12 dyspeptic patients with intact gallbladder, and 12 healthy controls. Specific symptoms were scored for severity and frequency. Gastrointestinal manometry was performed during 3 hr of fasting and 2 hr postprandially. Simultaneously, samples of duodenal and gastric contents were obtained sequentially for quantification of bile acids. Results show that symptom global severity (9.6 +/- 0.4 vs 8.8 +/- 0.7) and frequency (9.9 +/- 0.8 vs 9.0 +/- 0.5) were similar in both dyspeptic groups; only abdominal pain was milder in cholecystectomized patients (1.9 +/- 0.1 vs 2.6 +/- 0.2; P < 0.05). Fasting gastric bile acid concentrations were higher in cholecystectomized patients (P < 0.05) and antral postcibal motility lower (P < 0.05) than in the groups. No relation among gastric hypomotility, duodenogastric bile reflux, and symptom scores was detected. We concluded that patients with functional dyspepsia and a prior cholecystectomy have clinical features similar to those with gallbladders, but some physiological features are dissimilar: antral motility is decreased and duodenogastric bile reflux is increased. Thus, a uniform clinical expression of various pathophysiological disturbances constitutes the basis of functional dyspepsia.

Does Helicobacter pylori infection increase gastric sensitivity in functional dyspepsia?

The role of Helicobacter pylori infection in the pathogenesis of functional dyspepsia is debated. It is known that a substantial fraction of dyspeptic patients manifest a low discomfort threshold to gastric distension. This study investigated the symptomatic pattern in 27 H pylori positive and 23 H pylori negative patients with chronic functional dyspepsia, and potential relations between infection and gastric hyperalgesia. Specific symptoms (pain, nausea, vomiting, bloating/fullness, early satiety) were scored from 0 to 3 for severity and frequency (global symptom scores: 0-15). The mechanical and perceptive responses to gastric accommodation were evaluated with an electronic barostat that produced graded isobaric distensions from 0 to 20 mm Hg in 2 mm Hg steps up to 600 ml. Gastric compliance (volume/pressure relation) and perception (rating scale: 0-10) were quantified. Standard gastrointestinal manometry and recorded phasic pressure activity at eight separate sites during fasting and postprandially were also assessed. H pylori positive and H pylori negative patients manifested similar severity and frequency of specific symptoms and global symptom scores (mean (SEM)) (severity: 9.5 (2.0) v 9.0 (2.1); frequency: 10.8 (2.0) v 9.7 (2.2)). No differences were seen either in gastric compliance (53 (4) ml/mm Hg v 43 (3) ml/mm Hg) or in gastric perception of distension (slope: 0.50 (0.05) v 0.53 (0.06)). Postprandial antral motility was significantly decreased in H pylori positive patients (two hours motility index: 10.4 (0.6) v 12.6 (0.5); p < 0.05). It is concluded that H pylori infected patients with functional dyspepsia present no distinctive symptoms by comparison with H pylori negative counterparts and H pylori infection is associated with diminished postprandial antral motility but it does not increase perception of gastric distension.

[Value of endoscopic ultrasonography in the diagnosis of pancreatic and gastroduodenal endocrine tumors]. / Valor de la ecografía endoscópica en el diagnóstico de los tumores endocrinos pancreáticos y gastroduodenales.

OBJECTIVE: To present our experience in the localization of endocrine-gastroenteropancreatic tumors (EGPT) by endoscopic ultrasonography. METHODS: Endoscopic ultrasonography was performed in 10 patients with 13 pancreatic tumors and four in the digestive tract. RESULTS: Sensitivity and diagnostic efficacy were 69% and 70%, respectively. These values were greater than those observed by other image techniques. Also, additional diagnoses and other three tumors of less than 1 cm undiagnosed by ultrasonography (US), Computer Tomography (CT) and Magnetic Resonance (MR), were detected. Specificity was 80% because among five case-controls a false positive was found. With more experience and the possibility to find small tumors, USE should improve other image techniques in the diagnosis and localization of endocrine digestive tumors.

Improved image quality during abdominal ultrasonography by clebopride + simethicone.

The use of clebopride + simethicone (Flatoril) was assessed as a possible solution to the problem of ultrasound imaging of the pancreas area. A statistically significant improvement was found in head and body imaging of the pancreas (76%). This is due to simethicone's antiflatulence effect and the movement of gas towards the intestine and colon as a result of clebopride's gastrointestinal emptying effect.

[Steatorrhea and its treatment with pancreatic enzymes in endocrine tumors of the pancreas (pancreatic adenomas)]. / Esteatorrea y su tratamiento con fermentos pancreáticos en los tumores endocrinos del páncreas (apudomas pancreáticos).

We report the treatment of steatorrhea with pancreatic enzymes in four pancreatic endocrine tumors treated in our hospital. All four patients were males, with a mean age of 50 +/- 4.6, a basal steatorrhea of 10.8 +/- 3.7 g/24 h (N: less than 5 g/24 h), and a defecation rate of 1.8 +/- 0.8 (mean +/- SD). They were treated for one week with Pankreon 700 in the form of pills of 700 mg pancreatin (28,000 U lipase PIF, 22,000 U amylase PIF and 1,500 U protease PIF). They were given 15 pills/day divided into three doses. The mean steatorrhea dropped to 7.1 +/- 1.5 g/24 h. Then the patients were given Creon capsules with 300 mg pancreatin in pellets (8,000 U lipase PIF, 9,000 U amylase PIF and 450 U protease PIF). They were given six capsules/day divided into three doses, and the steatorrhea dropped to 7.2 +/- 4.1 g/24 h, while the rate of defecation dropped to 1/day. On comparison of the two products (Pankreon-- a classic form of pancreatin, and Creon-- a modern galenical in pellets), it was found that Creon achieved the same results as Pankreon 700 in a doses 2.5 times lower. This pilot study demonstrates that exocrine pancreatic insufficiency can be frequent in endocrine tumors of the pancreas, and although underestimated, it can be partially corrected with pancreatic enzymes.

[Ranitidine and cimetidine in long-term (2 years) maintenance therapy of chronic gastric ulcer]. / Ranitidina y cimetidina en la terapéutica de mantenimiento a largo plazo (dos años) de la úlcera gástrica crónica.

Sixty patients with chronic gastric ulcer (UGC) received randomly cimetidine (CMT) or ranitidine (RNT) for 2 years, at a dose of 400 mg/night CMT or 150 mg/night RNT, in a prospective, controlled, simple blind clinical trial of these medications and endoscopy findings. The objective was to evaluate the brute rate of symptomatic recurrences during maintenance therapy and the rate of asymptomatic ulcers up to the end of this period of treatment. Of the 60 patients with healed chronic gastric ulcer who began the trial, 12 abandoned treatment (20%), six in each group. In the group treated with CMT (n = 24) there were 10 symptomatic recurrences (41.6%), and in the group treated with RNT (n = 24), four symptomatic recurrences (16.6%). Differences, although near statistical significance, were not mathematically significant. The rate of endoscopic ulcers at the end two 2 years of maintenance treatment was 45.4% and 42.8%, respectively. There were no important secondary effects that obliged suspension of the medication. The conclusion that can be drawn from this study are that maintenance treatment with CMT and RNT reduce recurrences and complications, with a favorable therapeutic tendency for RNT; the majority of symptomatic recurrences appeared in the first year of therapy; the percentage of asymptomatic ulcers at the end of this therapy was reduced by almost 20%; and there were no statistically significant differences between CMT and RNT.